Besunyen Holdings Company Limited logo

Besunyen Holdings Company Limited

0926.HK

HKSEConsumer DefensivePackaged Foods

Latest quote

HK$2.50

+HK$0.05 · +2.04%

Aug 24, 3:55 PM HKT

0926.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Besunyen Holdings Company Limited, established in Beijing, China, in 2000, functions as a subsidiary of Foreshore Holding Group Limited. The company's core operations encompass the research, development, production, and distribution of therapeutic tea products and pharmaceutical goods throughout the People's Republic of China. Its product range includes a variety of therapeutic teas, prominently featuring the Besunyen brand, alongside specific offerings such as herbal tea, Besunyen Detox, and Besunyen slimming tea. Furthermore, functional teas, such as Besunyen Fit Tea, are also part of its portfolio. Within its pharmaceutical segment, Besunyen markets LARLLY Orlistat for weight loss and manufactures and sells over-the-counter (OTC) medications, including the Besunyen Orlistat weight-loss capsule. Its products reach consumers via an extensive distribution network that includes OTC pharmacies, retail locations in shopping centers and supermarkets, a network of distributors and sub-distributors, and various online e-commerce channels.

Industry
Packaged Foods
Sector
Consumer Defensive
Headquarters
CN
CEO
Bing Feng
Listed since
Sep 29, 2010
Employees
123

Market position

Day range

Current HK$2.50

52-week range

Current HK$2.50

Open
HK$2.50
Previous close
HK$2.45
Volume
17.5K
9.11× average
Average volume
1.92K
Average daily volume
Market cap
305.66M HKD
Beta
1.18
Market reference 1
50-day average
HK$2.4162
+3.47% above average
200-day average
HK$2.467
+1.34% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
89.41M CNY
P/E (TTM)
11.52×
P/B (TTM)
0.54×
P/S (TTM)
0.49×
EV / EBITDA
1.79×
Earnings yield
7.79%
Free cash flow yield
22.90%
Dividend yield
10.00%

Profitability & efficiency

Gross margin
75.21%
Operating margin
5.53%
Net margin
4.27%
Return on equity
4.36%
Return on assets
3.63%
Return on invested capital
3.64%

Financial health

Debt / equity
0.01×
Current ratio
2.98×
Altman Z-score
1.89
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends83%33%-18%-68%Gross margin, FY2021: 63.44%Gross margin, FY2022: 61.47%Gross margin, FY2023: 63.78%Gross margin, FY2024: 67.28%Gross margin, FY2025: 70.11%Operating margin, FY2021: -8.00%Operating margin, FY2022: -3.92%Operating margin, FY2023: -27.68%Operating margin, FY2024: 4.45%Operating margin, FY2025: 5.56%Net margin, FY2021: -13.23%Net margin, FY2022: -12.37%Net margin, FY2023: -55.12%Net margin, FY2024: 3.06%Net margin, FY2025: 4.14%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 63.44%. Gross margin FY2022 61.47%. Gross margin FY2023 63.78%. Gross margin FY2024 67.28%. Gross margin FY2025 70.11%. Operating margin FY2021 -8.00%. Operating margin FY2022 -3.92%. Operating margin FY2023 -27.68%. Operating margin FY2024 4.45%. Operating margin FY2025 5.56%. Net margin FY2021 -13.23%. Net margin FY2022 -12.37%. Net margin FY2023 -55.12%. Net margin FY2024 3.06%. Net margin FY2025 4.14%.

Income trends

Revenue

494.32M CNY+2.07%

Operating income

27.5M CNY+27.59%

Net income

20.44M CNY+38.09%
Income trends across reported periods1.24B CNY681.03M CNY120.87M CNY−439.28M CNYRevenue, FY2021: 1.1B CNYRevenue, FY2022: 801.34M CNYRevenue, FY2023: 542.88M CNYRevenue, FY2024: 484.3M CNYRevenue, FY2025: 494.32M CNYOperating income, FY2021: −88.1M CNYOperating income, FY2022: −31.38M CNYOperating income, FY2023: −150.29M CNYOperating income, FY2024: 21.55M CNYOperating income, FY2025: 27.5M CNYNet income, FY2021: −145.71M CNYNet income, FY2022: −99.09M CNYNet income, FY2023: −299.24M CNYNet income, FY2024: 14.8M CNYNet income, FY2025: 20.44M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.1B CNY. Revenue FY2022 801.34M CNY. Revenue FY2023 542.88M CNY. Revenue FY2024 484.3M CNY. Revenue FY2025 494.32M CNY. Operating income FY2021 −88.1M CNY. Operating income FY2022 −31.38M CNY. Operating income FY2023 −150.29M CNY. Operating income FY2024 21.55M CNY. Operating income FY2025 27.5M CNY. Net income FY2021 −145.71M CNY. Net income FY2022 −99.09M CNY. Net income FY2023 −299.24M CNY. Net income FY2024 14.8M CNY. Net income FY2025 20.44M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue494.32M CNY484.3M CNY542.88M CNY801.34M CNY1.1B CNY
Cost of goods sold147.74M CNY158.46M CNY196.66M CNY308.75M CNY402.6M CNY
Gross profit346.58M CNY325.84M CNY346.22M CNY492.59M CNY698.55M CNY
Research and development9.5M CNY29.36M CNY34.92M CNY33.87M CNY93.1M CNY
Selling, general, and administrative278.4M CNY247.64M CNY470.73M CNY489.39M CNY695.88M CNY
Operating expenses319.09M CNY304.29M CNY496.51M CNY523.97M CNY786.65M CNY
Interest income364.32K CNY7.82M CNY5.83M CNY1.82M CNY11.2M CNY
Interest expense360.42K CNY228K CNY2M CNY7.65M CNY5.42M CNY
Depreciation and amortization14.8M CNY13.29M CNY15.73M CNY18.28M CNY55.54M CNY
Operating income27.5M CNY21.55M CNY−150.29M CNY−31.38M CNY−88.1M CNY
Net income20.44M CNY14.8M CNY−299.24M CNY−99.09M CNY−145.71M CNY

Company facts updated Aug 24, 2026.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.25

2025 complete year-71.6% since 2015

Corporate action history

Dividend

Ex-dividend Aug 27, 2025

HK$0.15

Semi-Annual

Record Aug 28, 2025 · Payment Sep 12, 2025

Dividend

Ex-dividend Jun 18, 2025

HK$0.10

Semi-Annual

Record Jun 19, 2025 · Payment Jul 7, 2025

Dividend

Ex-dividend Sep 5, 2024

HK$0.90

Semi-Annual

Record Sep 6, 2024 · Payment Sep 23, 2024

Dividend

Ex-dividend May 28, 2021

HK$0.0375

Irregular

Record Jun 1, 2021 · Payment Jun 16, 2021

Dividend

Ex-dividend Oct 14, 2019

HK$0.11

Irregular

Record Oct 16, 2019 · Payment Oct 31, 2019

Dividend

Ex-dividend May 11, 2016

HK$0.05

Special

0926.HK peers

Continue in GoAI

Research 0926.HK

research.disclaimer